The Clinical Trials Portfolio for On-label and Off-label Studies of Eculizumab.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 31657842.
- Also identified by DOI 10.1001/jamainternmed.2019.4694 and PMC identifier 6820044.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
This study reviews publications and the level of evidence for US Food and Drug Administration–approved and off-label indications for eculizumab.
Medical subject headings
- Antibodies, Monoclonal, Humanized
- Atypical Hemolytic Uremic Syndrome
- Autoimmune Diseases
- Complement Inactivating Agents
- Hematologic Diseases
- Hemoglobinuria, Paroxysmal
- Kidney Diseases
- Myasthenia Gravis